How will ASCO combat cancer disparities?

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

The changing landscape of AML

Using bioinformatics and genomics to treat AML

Blinatumomab for relapsed/refractory Burkitt's lymphoma

Chemoimmunotherapy or BTK inhibition for patients with CLL

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Cancer care in Latin America

ASCO 2019 and vision for cancer control

Better education about breast cancer treatment in Africa

Predictive models for treatment risk in cancer

Improving radiotherapy access in Africa